Prosecution Insights
Last updated: November 08, 2026
Application No. 17/642,758

MODELING VARIABILITY IN RADIOSENSITIVITY AND TUMOR IMMUNE CONTEXTURE TO PERSONALIZE RADIOTHERAPY

Non-Final OA §101§112
Filed
Mar 14, 2022
Priority
Sep 13, 2019 — provisional 62/900,003 +1 more
Examiner
WHALEY, PABLO S
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Helmholtz Centre For Infection Research
OA Round
2 (Non-Final)
25%
Grant Probability
At Risk
2-3
OA Rounds
6m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
136 granted / 544 resolved
-35.0% vs TC avg
Strong +21% interview lift
Without
With
+21.4%
Interview Lift
resolved cases with interview
Typical timeline
5y 2m
Avg Prosecution
35 currently pending
Career history
595
Total Applications
across all art units

Statute-Specific Performance

§101
28.7%
-11.3% vs TC avg
§103
25.0%
-15.0% vs TC avg
§102
4.9%
-35.1% vs TC avg
§112
32.8%
-7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 544 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-11 are presently under examination. Priority This Application claims the benefit of U.S. Provisional Application No. 62/900,003, filed on September 13, 2019. Accordingly, this date is the effect filing date of the instant application. Information Disclosure Statement The information disclosure statement (IDS) document(s) submitted are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS document(s) has/have been fully considered by the examiner. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. The United States Patent and Trademark Office published revised guidance on the application of 35 U.S.C. § 101. USPTO’s 2019 Revised Patent Subject Matter Eligibility Guidance (“Guidance”). Under the Guidance, in determining what concept the claim is “directed to,” we first look to whether the claim recites: (1) any judicial exceptions, including certain groupings of abstract ideas (i.e., mathematical concepts, certain methods of organizing human activity such as a fundamental economic practice, or mental processes) (Guidance Step 2A, Prong 1); and (2) additional elements that integrate the judicial exception into a practical application (see MPEP § 2106.05(a)-(c), (e)-(h)) (Guidance Step 2A, Prong 2). Only if a claim (1) recites a judicial exception and (2) does not integrate that exception into a practical application, do we then look to whether the claim contains an “‘inventive concept’ sufficient to ‘transform’” the claimed judicial exception into a patent-eligible application of the judicial exception. Alice, 573 U.S. at 221 (quoting Mayo, 566 U.S. at 82). In so doing, we thus consider whether the claim: (3) adds a specific limitation beyond the judicial exception that are not “well-understood, routine and conventional in the field” (see MPEP § 2106.05(d)); or 2019 Revised Patent Subject Matter Eligibility Guidance, 84 Fed. Reg. 50-57 (January 7, 2019). (4) simply appends well-understood, routine, conventional activities previously known to the industry, specified at a high level of generality, to the judicial exception.(Guidance Step 2B). See Guidance, 84 Fed. Reg. at 54-56. Step 1 The instantly claimed invention (claim 1 being representative) is directed to a method of detecting the radiosensitivity of a tumor in a subject that requires performing a series of process steps. As such, the claims fall into one of the four statutory categories. A. Guidance Step 2A, Prong 1 The Revised Guidance instructs us first to determine whether any judicial exception to patent eligibility is recited in the claim. The Revised Guidance identifies three judicially-excepted groupings identified by the courts as abstract ideas: (1) mathematical concepts, (2) certain methods of organizing human behavior such as fundamental economic practices, and (3) mental processes. Regarding claim(s) 1, the following limitations constitute the abstract idea for the following reasons: measuring the individual radiation immune sensitivity (iRIS) phenotype of the tumor tissue sample by measuring the pre-radiation distance of tumor-immune ecosystem (TIES) to the immune mediated tumor elimination (IMTE) region, and the number of effector, suppressor and cancer cells; wherein a iRIS value lower than a median iRIS score (iRIS"O) indicates that a tumor is radiosensitive and an iRIS value above the median iRIS score (iRIShi) indicates that a tumor is radioresistant. Mental Processes In this case, the claimed ‘measuring’ step is not limited to any particular acts or operations to achieve the claimed function. Accordingly, under the BRI, this step encompasses the observation, collection, and manipulation of data, which may be practically performed in the human mind of a scientist (e.g. measuring distances and counting cells in order to obtain values). For these reasons, the above steps fall within the “mental processes” grouping of abstract ideas because they cover concepts performed in the human mind, including observation, evaluation, judgment, and opinion. See MPEP 2106.04(a)(2), subsection III [Step 2A, Prong 1: YES]. Mathematical Concept In addition, under the BRI, the above measuring step additionally requires performing distance calculations (to obtain values) and comparing them to threshold values. Accordingly, this step also encompasses calculations and mathematically relating data. See MPEP 2106.04(a)(2). A review of the specification also teaches specific mathematical equations for performing the claimed functions [page 19-20]. Therefore, when read in light of the specification, the claimed predicting step also encompasses a mathematical concept. B. Guidance Step 2A, Prong 2 This part of the eligibility analysis evaluates whether the claim includes any additional steps/elements that integrate the recited judicial exception into a practical application of the exception. In this case, the additional steps/elements that are not part of the abstract idea are as follows: Obtaining a tumor tissue sample; The obtaining step is not limited to any particular techniques or devices and the sample is merely for use by the abstract idea. Therefore, this step amounts to insignificant extra-solution activity and is not indicative of an integration into a practical application. See MPEP 2106.05(g). Even when viewed in combination, these additional steps/elements do not integrate the recited judicial exception into a practical application. [Step 2A, Prong 2: NO] Notably, MPEP 2106.04(d)(1) lists the following considerations for evaluating whether additional elements integrate a judicial exception into a practical application: An improvement in the functioning of a computer, or an improvement to other technology or technical field, as discussed in MPEP §§ 2106.04(d)(1) and 2106.05(a); Applying or using a judicial exception to affect a particular treatment or prophylaxis for a disease or medical condition, as discussed in MPEP § 2106.04(d)(2); Implementing a judicial exception with, or using a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim, as discussed in MPEP § 2106.05(b); Effecting a transformation or reduction of a particular article to a different state or thing, as discussed in MPEP § 2106.05(c); and Applying or using the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception, as discussed in MPEP § 2106.05(e). Additionally, the courts have also identified limitations that did not integrate a judicial exception into a practical application: Merely reciting a phrase such as "apply it" (or an equivalent) along with the judicial exception, or merely including instructions to implement an abstract idea on a computer, or merely using a computer as a tool to perform an abstract idea, as discussed in MPEP 2106.05(f); Adding insignificant extra-solution activity to the judicial exception, as discussed in MPEP 2106.05(g); and Generally linking the use of a judicial exception to a particular technological environment or field of use, as discussed in MPEP 2106.05(h). C. Guidance Step 2B: Under the 2019 PEG, a conclusion that an additional element is insignificant extra-solution activity in Step 2A should be re-evaluated in Step 2B. In this case, the claims do not include additional steps and/or elements appended to the judicial exception that are sufficient to amount to significantly more than the judicial exception(s) for the following reasons: As discussed above, the non-abstract steps (including the full limitations and not just the verbs) amount to nothing more than insignificant extra-solution activity. In addition, Scott et al. (Lancet Oncol. 2017 February ; 18(2): 202–211) teaches a genome-based model for adjusting radiotherapy dosages that includes obtaining tumor samples [see entire]. Accordingly, there is nothing unconventional with regards to how the samples are being obtained. In addition, to the extent that applicant intends for the claimed analysis to be performed by a computer, the courts have also explained that the use of generic computer elements do not alone transform an otherwise abstract idea into patent-eligible subject matter. See DDR Holdings (Fed. Cir. 2014). Even when considered in combination, these additional steps/elements do not provide an inventive concept [Step 2B: NO]. Dependent Claims Dependent claims 2-4 have also been considered under the two-part analysis but do not include additional steps/elements appended to the judicial exception that are sufficient to amount to significantly more than the judicial exception(s) for the following reasons. Regarding claim(s) 2-4, these claims further limit the specificity of the abstract idea set forth above. Accordingly, these claims are also directed to abstract ideas for reasons set forth above (Step 2A, prong 1). Therefore, the instantly rejected claims are not drawn to eligible subject matter as they are directed to an abstract idea without significantly more. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-11 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description requirement is separate and distinct from the enablement requirement. The specification must: (1) describe the claimed invention in a manner understandable to a person of ordinary skill in the art, and (2) show that the inventor actually invented the claimed subject matter. In this case, the instant specification fails to provide written description support for the following reasons. Claim 1 recites “measuring the individual radiation immune sensitivity (iRIS) phenotype of the tumor tissue sample by measuring the pre-radiation distance of tumor-immune ecosystem (TIES) to the immune mediated tumor elimination (IMTE) region, and the number of effector, suppressor and cancer cells; wherein a iRIS value lower than a median iRIS score (iRISlo) indicates that a tumor is radiosensitive and an iRIS value above the median iRIS score (iRIShi) indicates that a tumor is radioresistant. Claim 10 recites “measuring the individual radiation immune sensitivity (iRIS), wherein a tumor tissue sample from a cancer that has an iRIS score lower than a median iRIS score is designated as iRISO; measuring the radio sensitivity index (RSI) of the tumor tissue sample, wherein a RSI value lower than a median RSI score is designated as RSI'; and administering to the subject a total dosage of radiation; wherein the total dosage of radiation is administered over several fractions; and wherein the total number of fractions administered is less than 20 when the iRIS/RSI phenotype is iRISlo/RSIlo; and wherein the total number of fractions administered is greater than 20 when the iRIS/RSI phenotype is iRISlo/RSIhi, iRIShi/RSIlo, or iRIShi/RSIhi. As best understood, the claimed invention purports to be able to detect radiosensitivity of a tumor in a subject merely based on the “distance” between generically recited parameters (e.g. TIES, IMTE, and number of effector, surpressor, and cancer cells) and IRIS scores, and performing dosage adjustments based on IRIS/RSI ratios. The claims are not limited to any particular type of tumor/cancer or associated genes. The claims are not limited to any particular equations for achieving the claimed results, i.e. the claims broadly encompass all forms of analysis that would serve to achieve the intended result. A review of the specification does not describe, to any appreciable extent, any algorithms or mathematical operations that achieve the above function for the full scope of what is being claimed. At best, a review of the specification teaches a limited embodiment, namely an equation for calculating IRIS using vector coordinates of all TIESs in the region of the IMTE, such that min(dIMTE) denotes the trajectory with the shortest Euclidean distance from the current TIES of immune evasion to one of immune-mediated control [page 20] and calculating RSI [page 21]. However, this is not commensurate in scope with what is being claimed and it is improper to import narrowing limitations into the claims. MPEP 2111.01. Moreover, one of ordinary skill in the art would recognize that computational methods for predicting radiosensitivity of a tumor are not trivial. Torres-Roca et al. (US 20090076734 A1; Pub. Date: 2009-03-19) teaches computer-implemented methods for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor. In particular, unlike the claimed method, Torres-Roca requires assigning a radiation sensitivity index to the cell based on expression levels of two or more signature genes selected from the group of specific genes [abstract, ref. claims 1-15], and generating RSIs based on linear regression models applied to the gene expression data [ref. claims 2-3]. Scott et al. (Lancet Oncol. 2017 February ; 18(2): 202–211) teaches a genome-based model for adjusting radiotherapy dosages. In particular, unlike the instant claims, Scott teaches developing and validating a patient-specific multivariable model for predicting therapeutic effects of radiotherapy using specific a patient population, specific type of cancer, tumor specific genomic data, and specific radiosensitivity index genes associated with the tumors [Methods and Discussion]. Chen et al. (Scientific Reports, 2018, volume 8, Article number: 11934, pp.1-10) teaches that the role of immune modulation in the tumor microenvironment invoked by radiotherapy in radiosensitivity is poorly defined and that some tumor cells are more radiosensitive than the others [Abstract]. Lastly, to the extent that the claimed invention requires using RSI metrics to adjust dosages, the post-filing art of Mistry (“Radiosensitivity Index” (“RSI”) is not fit to be used for dose-adjustments: a pan-cancer analysis”; Pub. Date: 08/23/2021, pp.1-6) teaches that the RSI (radiosensitivity index) is not a suitable marker for predicting radiosensitivity is not fit for making dosage adjustments. It is that none of the cited art references teach predicting radiosensitivity of a tumor using an IRIS metric that is based on distances between TIES and IMTE region and a number of effector, supressor, and cancer cells, and administering a total dosage of radiation over several fractions based on iRIS/RSI ratios as claimed. For these reasons, the instant specification does not provide sufficient evidence that applicant has actually developed and validated mathematical models capable of detecting radiosensitivity of a tumor for the full scope of what is being claimed, i.e. merely based on distances between TIES and IMTE region and a number of effector, supressor, and cancer cells. To the extent that mathematical models are interpreted as structures, there is this is also no evidence that applicant has actually disclosed sufficient correlations between the claimed parameters (i.e. structure) and detecting radiosensitivity (i.e. function) for the full scope of models, cells, and types of cancer embraced by the claims. “[A] sufficient description of a genus requires the disclosure of either a representative number* of species falling within the scope of the genus or structural features common to the members of the genus so that one of skill in the art can 'visualize or recognize' the members of the genus” (AbbVie, 759 F.3d at 1297, reiterating Eli Lilly, 119 F.3d at 1568-69)(emphasis added). Applicant is reminded that a “mere wish or plan” for obtaining the claimed invention is not sufficient. (Centocor v. Abbott, 1348, citing Regents of the University of California v. Eli Lilly Co., 119 F.3d 1559 (Fed. Cir. 1997)). For the reasons discussed above, the specification does not satisfy the written description requirement with respect to the full scope of what is being claimed. For more information regarding the written description requirement, see MPEP §2161.01- §2163.07(b). Claim rejections - 35 USC § 112 - Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims that depend directly or indirectly from claim(s) 1 and 10 is/are also rejected due to said dependency. Claim 1 recites “measuring the individual radiation immune sensitivity (iRIS) phenotype of the tumor tissue sample by measuring the pre-radiation distance of tumor-immune ecosystem (TIES) to the immune mediated tumor elimination (IMTE) region, and the number of effector, suppressor and cancer cells”. It is unclear as to the metes and bounds of the claimed “measuring” such that the artisan would recognize what computational acts and/or operations are encompassed. In particular, this step appears to be relying on ‘measuring’ information associated with specific variables/parameters (e.g. TIES, IMTE region, cell counts) that have not even been defined or previously determined. A review of the specification teaches an equation for calculating IRIS using vector coordinates of all TIESs in the region of the IMTE, such that min(dIMTE) denotes the trajectory with the shortest Euclidean distance from the current TIES of immune evasion to one of immune-mediated control [page 20]. However, this is not commensurate in scope with what is being claimed and it is improper to import narrowing limitations into the claims. MPEP 2111.01. Accordingly, it is unclear what steps and/or operations are encompassed by said “measuring”. Clarification is requested via amendment. Claim 1 recites “wherein a iRIS value lower than a median iRIS score (iRISlo) indicates that a tumor is radiosensitive and an iRIS value above the median iRIS score (iRIShi) indicates that a tumor is radioresistant.” The above “wherein” clause suggests additional method steps without positively reciting them (e.g. classification of IRIS scores, calculating median scores, comparing scores to a threshold). Applicant is reminded that claim scope is not limited by claim language that suggests or makes optional but does not require steps to be performed. See MPEP 2111.04. Accordingly, for reasons set forth above, it is unclear what limiting effect is intended by the claimed “wherein” clause such that one of ordinary skill in the art would know how to avoid infringement. Clarification is requested via amendment. Claim 5 recites “further comprising administering fewer fractions of a total radiation dose to a subject with a tumor that has an iRISlo/RSIlo phenotype.” The above limitation is problematic because it requires the use of information that has not been previously determined, e.g. calculating various types of IRIS/RSI ratios. Accordingly, there is lack of antecedent basis for the claimed ratio. In addition, the claim also appears to be missing essential subject matter (e.g. calculating the claimed ratio). Clarification is requested via amendment. Claim 3 recites “measuring radiosensitivity index (RSI) of the tumor…”. In this case, it is unclear as to metes and bounds of the claimed “RSI” such that the artisan would recognize what computational acts and/or operations are encompassed, i.e. the claimed “measuring” merely states overall objectives. One of ordinary skill in the art of genomics, for example, would recognize that the RSI is merely a metric that aims to predict how sensitive a tumor is to radiation therapy, i.e. a model. However, the instant specification does not provide any limiting definition or well-defined models associated with this term that would serve to clarify the scope. At best, the specification teaches generical statistical methods for calculating an RSI [page 21]. However, this is not commensurate in scope with what is being claimed and it is improper to import narrowing limitations into the claims. MPEP 2111.01. Accordingly, it is unclear what steps and/or operations are encompassed by said “measuring”. Clarification is requested via amendment. Claim 3 recites “…indicates that eh tumor is radioresistant” (last line). In this case, it is unclear what is meant by “eh tumor”. The specification does not provide any limiting definition that would serve to clarify the scope. The examiner believes this to be a grammatical error. Clarification is requested via amendment. Claim 7 recites “further comprising administering more fractions of a total radiation dose to a subject with a tumor that has an iRISlo/RSIhi, iRIShi/RSIlo, or iRIShi/RSIhi phenotype.” The above limitation is problematic because it requires the use of information that has not been previously determined, e.g. calculating various types of IRIS/RSI ratios. Accordingly, there is lack of antecedent basis for the claimed ratios. In addition, the claim also appears to be missing essential subject matter (e.g. calculating the claimed ratios). Clarification is requested via amendment. Claim 9 recites “the method of detecting the radiosensitivity of a tumor of claim 1, wherein the radiation dose per fraction administered is between 1.5 and 2.5 GY.” This step amounts to a generic functional limitation that does not appear to use any of the information generated from parent claim 1. As such, there is also lack of antecedent basis for “the radiation dose…administered…” (as there is no previous step for administering anything in parent claim 1). Correction is requested via amendment. Claim 10 recites “measuring the individual radiation immune sensitivity (iRIS), wherein a tumor tissue sample from a cancer that has an iRIS score lower than a median iRIS score is designated as iRISO; measuring the radio sensitivity index (RSI) of the tumor tissue sample, wherein a RSI value lower than a median RSI score is designated as RSI'; and administering to the subject a total dosage of radiation; wherein the total dosage of radiation is administered over several fractions”. It is unclear as to the metes and bounds of the claimed “measuring” such that the artisan would recognize what computational acts and/or operations are encompassed, i.e. the claimed “measuring” merely states overall objectives. A review of the specification teaches an equation for calculating IRIS using vector coordinates of all TIESs in the region of the IMTE, such that min(dIMTE) denotes the trajectory with the shortest Euclidean distance from the current TIES of immune evasion to one of immune-mediated control [page 20] and calculating RSI [page 21]. However, this is not commensurate in scope with what is being claimed and it is improper to import narrowing limitations into the claims. MPEP 2111.01. Accordingly, it is unclear what steps and/or operations are encompassed by said “measuring”. Clarification is requested via amendment. Claim 10 recites “and wherein the total number of fractions administered is less than 20 when the iRIS/RSI phenotype is iRISlo/RSIlo; and wherein the total number of fractions administered is greater than 20 when the iRIS/RSI phenotype is iRISlo/RSIhi, iRIShi/RSIlo, or iRIShi/RSIhi.” The above “wherein” clause suggests additional method steps without positively reciting them (e.g. calculating various IRIS/RSI ratios, comparing the ratios to a threshold). Applicant is reminded that claim scope is not limited by claim language that suggests or makes optional but does not require steps to be performed. See MPEP 2111.04. Accordingly, for reasons set forth above, it is unclear what limiting effect is intended by the claimed “wherein” clause such that one of ordinary skill in the art would know how to avoid infringement. In addition, the above limitation is problematic because it requires the use of information that has not been previously determined, e.g. calculating various types of IRIS/RSI ratios. Accordingly, the claim also appears to be missing essential subject matter. Clarification is requested via amendment. Cited Prior Art The following prior art made of record and not relied upon is considered pertinent to applicant' s disclosure. Eschrich et al. (Int. J. Radiation Oncology Biol. Phys., Vol. 75, No. 2, pp. 489–496, 2009) teaches method for developing and validating a gene expression model to predict intrinsic radiosensitivity and treatment response in patients. Torres-Roca et al. (US 20090076734 A1; Pub. Date: 2009-03-19) teaches mathematical models and computer-implemented methods for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor. In particular, the method requires assigning a radiation sensitivity index to the cell based on expression levels of two or more signature genes in the cell, wherein the two or more signature genes are selected from the group consisting of Androgen receptor (AR); Jun oncogene (c-Jun); Signal transducer and activator of transcription 1 (STAT1); Protein kinase C, beta (PRKCB or PKC); V-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA or p65); c-Abl oncogene 1, receptor tyrosine kinase (ABL1 or c-Abl); SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) (SUMO1); CDK1 (p34); Histone deacetylase 1 (HDAC1); and Interferon regulatory factor 1 (IRF1); wherein the radiation sensitivity index indicates whether the cell is sensitive to radiation therapy. Scott et al. (WO 2016179422 A1) teaches a method of treating a subject having a tumor, wherein the method can include determining a radiosensitivity index of the tumor, deriving a subject-specific variable based on the radiosensitivity index, and obtaining a genomic adjusted radiation dose effect value for the tumor. The radiosensitivity index can be assigned from expression levels of signature genes of a cell of the tumor. Additionally, the genomic adjusted radiation dose effect value can be predictive of tumor recurrence in the subject after treatment. The method can also include determining a radiation dose based on the subject-specific variable and the genomic adjusted radiation dose effect value. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PABLO S WHALEY whose telephone number is (571)272-4425. The examiner can normally be reached between 1pm-9pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anita Coope can be reached at 571-270-3614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PABLO S WHALEY/Primary Examiner, Art Unit 3619
Read full office action

Prosecution Timeline

Mar 14, 2022
Application Filed
Aug 14, 2025
Non-Final Rejection mailed — §101, §112
Jan 09, 2026
Response Filed
Aug 04, 2026
Response after Non-Final Action
Aug 27, 2026
Request for Continued Examination
Aug 28, 2026
Response after Non-Final Action
Nov 06, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12718954
Unsupervised Machine Learning Methods
2y 0m to grant Granted Aug 25, 2026
Patent 12688905
SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS
2y 12m to grant Granted Jul 21, 2026
Patent 12633374
METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT
4y 11m to grant Granted May 19, 2026
Patent 12620473
A METHOD AND DOSING CONTROLLER FOR ADMINSTERING A CORRECTION DOSE OF INSULIN
2y 11m to grant Granted May 05, 2026
Patent 12288620
A METHOD AND SYSTEM FOR INSULIN MANAGEMENT
1y 7m to grant Granted Apr 29, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
25%
Grant Probability
46%
With Interview (+21.4%)
5y 2m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 544 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month